Equillium announces abstract accepted for presentation at acr convergence 2022

La jolla, calif.--(business wire)---- $eq #gvhd--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that an abstract was accepted for presentation at acr convergence, the annual meeting of the american college of rheumatology. the meeting, the world's premier virtual rheumatology experience, will take place online november 10 – 14, 2022 at the pennsylv
EQ Ratings Summary
EQ Quant Ranking